References

• Seshadri, A., Prokop, L. J., & Singh, B. (2024). Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for major depression: A systematic review and meta-analysis. Journal of Affective Disorders, 356, 379–384. https://doi.org/10.1016/j.jad.2024.03.137
• Oliver, P. A., Snyder, A. D., Feinn, R., Malov, S., McDiarmid, G., & Arias, A. J. (2022). Clinical effectiveness of intravenous racemic ketamine infusions in a large community sample of patients with treatment-resistant depression, suicidal ideation, and generalized anxiety symptoms: A retrospective chart review. Journal of Clinical Psychiatry, 83(6), 21m14336. https://doi.org/10.4088/JCP.21m14336
• Perera, T., George, M. S., Grammer, G., Janicak, P. G., Pascual-Leone, A., & Wirecki, T. S. (2016). The Clinical TMS Society consensus review and treatment recommendations for TMS therapy for major depressive disorder. Brain Stimulation, 9(3), 336–346. https://doi.org/10.1016/j.brs.2016.03.010
• Rae Olmsted, K. L., Bartoszek, M., Mulvaney, S., McLean, B., Turabi, A., Young, R., Kim, E., Vandermaas-Peeler, R., Morgan, J. K., Constantinescu, O., Kane, S., Nguyen, C., Hirsch, S., Munoz, B., Wallace, D., Croxford, J., Lynch, J. H., White, R., & Walters, B. B. (2020). Effect of stellate ganglion block treatment on posttraumatic stress disorder symptoms: A randomized clinical trial. JAMA Psychiatry, 77(2), 130–138. https://doi.org/10.1001/jamapsychiatry.2019.3474